In order to develop its central nervous system (CNS) portfolio, Otsuka Pharmaceutical has agreed to acquire Neurovance for US$100 M upfront and more than US$150 M in potential milestone payments. Neurovance’s lead candidate, centanafadine (CTN or EB-1020), is a Phase III-ready triple reuptake inhibitor for the treatment of attention deficit hyperactivity disorder (ADHD) which has stimulant-like efficacy but without the limitations of stimulants. Otsuka will be hoping the drug will plug the revenue gap left by the loss of patent exclusivity of its blockbuster drug, Abilify® (aripiprazole).